From the Research
Hidradenitis suppurativa in pregnant women should be managed with careful consideration of treatment options, prioritizing the safety of both the mother and the fetus, and the most recent evidence suggests that topical clindamycin is a safe option for mild cases 1. When managing hidradenitis suppurativa (HS) in pregnant women, it is essential to consider the potential risks and benefits of each treatment option.
- Gentle cleansing of affected areas with antibacterial soap
- Wearing loose-fitting clothing
- Applying warm compresses to painful lesions For moderate to severe flares, oral antibiotics like cephalexin (500mg four times daily) or clindamycin (300mg three times daily) can be used for short courses, as they are generally considered safe during pregnancy 1. However, tetracyclines (doxycycline, minocycline) should be avoided as they can affect fetal bone and tooth development, despite their efficacy in treating HS, as shown in a prospective study published in 2021 2. Biologics like adalimumab should be discussed with both dermatology and obstetrics specialists, as decisions must be individualized, and surgery for draining abscesses can be performed if necessary, using local anesthesia. Regular follow-up with healthcare providers is essential, as HS may worsen during pregnancy due to hormonal changes, increased sweating, and weight gain. After delivery, a more comprehensive treatment plan can be developed if breastfeeding considerations allow. It is crucial to prioritize the safety of both the mother and the fetus when managing HS during pregnancy, and the treatment plan should be tailored to the individual patient's needs, based on the most recent and highest quality evidence available 1.